Filter Results
:
(994)
Show Results For
-
All HBS Web
(2,447)
- Faculty Publications (994)
Show Results For
-
All HBS Web
(2,447)
- Faculty Publications (994)
Page 1 of
994
Results
→
- June 2024
- Article
The Monitoring Role of Social Media
By: Jonas Heese and Joseph Pacelli
In this study, we examine whether social media activity can reduce corporate misconduct. We use the staggered introduction of 3G mobile broadband access across the United States to identify exogenous increases in social media activity and test whether access to 3G...
View Details
Keywords:
Corporate Misconduct;
Twitter;
Corporate Accountability;
Mobile and Wireless Technology;
Social and Collaborative Networks
Heese, Jonas, and Joseph Pacelli. "The Monitoring Role of Social Media." Review of Accounting Studies 29, no. 2 (June 2024): 1666–1706.
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Product Development;
Health Testing and Trials;
Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- May 2024
- Article
True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period
By: Julia C. Bulman, Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook and Ammar Sarwar
The study used time-driven activity-based costing (TDABC) to estimate the costs to perform uterine artery embolization (UAE). Utilization times for patients undergoing outpatient UAE for fibroids or adenomyosis were captured from electronic health record timestamps and...
View Details
Bulman, Julia C., Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook, and Ammar Sarwar. "True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period." Journal of the American College of Radiology 21, no. 5 (May 2024): 721–728.
- April 29, 2024
- Editorial
Stemming the Ripple Effect of Untreated Mental Illness: A Prescription for Change: Reimagining U.S. Healthcare
By: Lidia Moura and Susanna Gallani
Moura, Lidia, and Susanna Gallani. "Stemming the Ripple Effect of Untreated Mental Illness: A Prescription for Change: Reimagining U.S. Healthcare." Psychology Today (website) (April 29, 2024).
- April 2024
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of...
View Details
Keywords:
Cost vs Benefits;
Decisions;
Judgments;
Values and Beliefs;
Global Strategy;
Health Care and Treatment;
Patents;
Growth and Development Strategy;
Growth Management;
Product Positioning;
Supply and Industry;
Supply Chain;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Philanthropy and Charitable Giving;
Opportunities;
Social Issues;
Equality and Inequality;
Pharmaceutical Industry;
Health Industry;
Denmark;
United States;
Europe;
China;
India;
Middle East;
North Africa
- March–April 2024
- Article
Retailers and Health Systems Can Improve Care Together
By: Robert S. Huckman, Vivian S. Lee and Bradley R Staats
Health systems are struggling to address the many shortcomings of health care delivery: rapidly growing costs, inconsistent quality, and inadequate and unequal access to primary and other types of care. However, if retailers and health systems were to form strong...
View Details
Keywords:
Health Care;
Retail;
Retailers;
Consumer;
Health Care and Treatment;
Value;
Consumer Behavior;
Business Model;
Partners and Partnerships;
Health Industry;
Retail Industry;
United States
Huckman, Robert S., Vivian S. Lee, and Bradley R Staats. "Retailers and Health Systems Can Improve Care Together." Harvard Business Review 102, no. 2 (March–April 2024): 120–127.
- 2023
- Working Paper
An Experimental Design for Anytime-Valid Causal Inference on Multi-Armed Bandits
By: Biyonka Liang and Iavor I. Bojinov
Typically, multi-armed bandit (MAB) experiments are analyzed at the end of the study and thus require the analyst to specify a fixed sample size in advance. However, in many online learning applications, it is advantageous to continuously produce inference on the...
View Details
Liang, Biyonka, and Iavor I. Bojinov. "An Experimental Design for Anytime-Valid Causal Inference on Multi-Armed Bandits." Harvard Business School Working Paper, No. 24-057, March 2024.
- 2024
- Working Paper
Anytime-Valid Inference in Linear Models and Regression-Adjusted Causal Inference
By: Michael Lindon, Dae Woong Ham, Martin Tingley and Iavor I. Bojinov
Linear regression adjustment is commonly used to analyze randomized controlled experiments due to its efficiency and robustness against model misspecification. Current testing and interval estimation procedures leverage the asymptotic distribution of such estimators to...
View Details
Lindon, Michael, Dae Woong Ham, Martin Tingley, and Iavor I. Bojinov. "Anytime-Valid Inference in Linear Models and Regression-Adjusted Causal Inference." Harvard Business School Working Paper, No. 24-060, March 2024.
- 2024
- Working Paper
Design of Panel Experiments with Spatial and Temporal Interference
By: Tu Ni, Iavor Bojinov and Jinglong Zhao
One of the main practical challenges companies face when running experiments (or A/B tests) over a panel is interference, the setting where one experimental unit's treatment assignment at one time period impacts another's outcomes, possibly at the following time...
View Details
Keywords:
Research
Ni, Tu, Iavor Bojinov, and Jinglong Zhao. "Design of Panel Experiments with Spatial and Temporal Interference." Harvard Business School Working Paper, No. 24-058, March 2024.
- 2023
- Working Paper
Design-Based Inference for Multi-arm Bandits
By: Dae Woong Ham, Iavor I. Bojinov, Michael Lindon and Martin Tingley
Multi-arm bandits are gaining popularity as they enable real-world sequential decision-making across application areas, including clinical trials, recommender systems, and online decision-making. Consequently, there is an increased desire to use the available...
View Details
Ham, Dae Woong, Iavor I. Bojinov, Michael Lindon, and Martin Tingley. "Design-Based Inference for Multi-arm Bandits." Harvard Business School Working Paper, No. 24-056, March 2024.
- 2024
- Working Paper
Choosing and Using Information in Evaluation Decisions
By: Katherine Baldiga Coffman, Scott Kostyshak and Perihan O. Saygin
Most studies of gender discrimination consider how male versus female candidates are assessed given otherwise identical information about them. But, in many settings of interest, evaluators have a choice about how much information to acquire about a candidate before...
View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that...
View Details
Keywords:
Policy;
Government Legislation;
Health Care and Treatment;
Negotiation;
Price;
Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- 2024
- Working Paper
Cicely Saunders and the Modern Hospice Movement: A Brother's View
By: Amar Bhide and Srikant M. Datar
This Case history describes the role of Dame Cicely Saunders (1918- 2005) in
shaping the modern hospice movement. It is narrated in the first person through the words of her
brother, Christopher Saunders (1926-2024) as told to one of the authors of this paper.
View Details
Bhide, Amar, and Srikant M. Datar. "Cicely Saunders and the Modern Hospice Movement: A Brother's View." Harvard Business School Working Paper, No. 24-055, February 2024.
- 2023
- Working Paper
'De Gustibus' and Disputes about Reference Dependence
By: Thomas Graeber, Pol Campos-Mercade, Lorenz Goette, Alexandre Kellogg and Charles Sprenger
Existing tests of reference-dependent preferences assume universal loss aversion. This paper examines the implications of heterogeneity in gain-loss attitudes for such tests. In experiments on labor supply and exchange behavior we measure gain-loss attitudes and then...
View Details
Graeber, Thomas, Pol Campos-Mercade, Lorenz Goette, Alexandre Kellogg, and Charles Sprenger. "'De Gustibus' and Disputes about Reference Dependence." Harvard Business School Working Paper, No. 24-046, January 2024.
- 2024
- Article
Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway
By: Mateo Aboy, Cristina Crespo and Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Care and Treatment;
Technology Adoption;
Technological Innovation;
Safety;
Medical Devices and Supplies Industry;
United States
Aboy, Mateo, Cristina Crespo, and Ariel Stern. "Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway." Art. 29. npj Digital Medicine 7 (2024).
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Laws and Statutes;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- January 19, 2024
- Article
Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder
By: Robert S. Kaplan and Sarah E. Wakeman
U.S. overdose deaths currently exceed 100,000 per year. New facilities, known as bridge clinics, are broadening access to high-quality care by offering outpatient substance use disorder (SUD) treatment with few access barriers. But many of the critical services offered...
View Details
Kaplan, Robert S., and Sarah E. Wakeman. "Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder." Health Affairs Forefront (January 19, 2024).
- 2024
- Working Paper
Contributing to Growth? The Role of Open Source Software for Global Startups
By: Nataliya Langburd Wright, Frank Nagle and Shane Greenstein
Does participating in open source software (OSS) communities spur entrepreneurial growth? More
efficiently developing shared code, learning from what the OSS community has developed, and
shaping the direction of massive projects, such as those linked to frameworks...
View Details
Keywords:
Applications and Software;
Open Source Distribution;
Entrepreneurship;
Business Growth and Maturation;
Human Capital;
Valuation;
Corporate Strategy
Wright, Nataliya Langburd, Frank Nagle, and Shane Greenstein. "Contributing to Growth? The Role of Open Source Software for Global Startups." Harvard Business School Working Paper, No. 24-040, January 2024.
- January 2024
- Background Note
Evaluating Innovations in the Organization of Primary Care: What Type of Innovation Is It and How Well Does It Align with the Six Factors?
By: Regina E. Herzlinger and James Wallace
How can we evaluate if innovative health care ventures can do good—benefit society—and do well—become financially viable? This question is the topic of the first module in the Innovating in Health Care course book.
This note and "Health Stop (A): What Type... View Details
This note and "Health Stop (A): What Type... View Details
- January 2024
- Article
A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder
By: Sarah E. Wakeman, Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe and Robert S. Kaplan
The US fee-for-service payment system under-reimburses clinics offering access to comprehensive treatments for opioid use disorder (OUD). The funding shortfall limits a clinic’s ability to expand and improve access, especially for socially marginalized patients with...
View Details
Wakeman, Sarah E., Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe, and Robert S. Kaplan. "A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder." Journal of Behavioral Health Services & Research 51, no. 1 (January 2024): 22–30.